Misplaced Pages

Evocalcet

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Evocalcet
Clinical data
Trade namesOrkedia
ATC code
Identifiers
IUPAC name
  • 2-amino]pyrrolidin-1-yl]phenyl]acetic acid
CAS Number
PubChem CID
DrugBank
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H26N2O2
Molar mass374.484 g·mol

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism. It acts as a calcium-sensing receptor agonist.

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.

References

  1. Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. Bibcode:2018PLoSO..1395316K. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
  2. Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
  3. "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.
Calcium homeostasis (H05)
Parathyroid hormone and analogues
Anti-parathyroid hormone agents
Calcitonin derivatives
Calcimimetics
Other


Stub icon

This hormonal preparation article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Evocalcet Add topic